Coherus Oncology, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Coherus Oncology, Inc. (CHRS) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$33.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-05
- Coherus Oncology, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$33.35M.
- Coherus Oncology, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$36.94M.
- Coherus Oncology, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$46.35M.
- Coherus Oncology, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$44.52M.
- Coherus Oncology, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$183.12M.
- Coherus Oncology, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$215.39M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$33.35M 10-Q · filed 2026-08-05 | -$70.28M 10-Q · filed 2026-08-05 | -$116.63M derived: sum of 3 quarters · filed 2026-08-05 | -$161.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$36.94M 10-Q · filed 2026-05-11 | -$83.28M derived: sum of 2 quarters · filed 2026-05-11 | -$127.80M derived: sum of 3 quarters · filed 2026-05-11 | -$172.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$46.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$90.86M derived: sum of 2 quarters · filed 2026-03-09 | -$135.73M derived: sum of 3 quarters · filed 2026-08-05 | -$183.12M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$44.52M 10-Q · filed 2025-11-06 | -$89.38M derived: sum of 2 quarters · filed 2026-08-05 | -$136.78M 10-Q · filed 2025-11-06 | -$182.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$44.86M 10-Q · filed 2026-08-05 | -$92.26M 10-Q · filed 2026-08-05 | -$138.35M derived: sum of 3 quarters · filed 2026-08-05 | -$185.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$47.40M 10-Q · filed 2026-05-11 | -$93.49M derived: sum of 2 quarters · filed 2026-05-11 | -$141.09M derived: sum of 3 quarters · filed 2026-05-11 | -$195.94M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$46.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$93.69M derived: sum of 2 quarters · filed 2026-03-09 | -$148.54M derived: sum of 3 quarters · filed 2026-03-09 | -$215.39M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$47.60M 10-Q · filed 2025-11-06 | -$102.45M derived: sum of 2 quarters · filed 2025-11-06 | -$169.30M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$54.85M 10-Q · filed 2025-08-07 | -$122.89M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$68.04M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$221.76M 8-K · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |